E
Exscientia
Applying artificial intelligence and big data processing to accelerate discovery and development of drugs
At a glance
- Listing
- IPO 2021
Open roles
Exscientia in the Oxford ecosystem
The Exscientia office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later17 investors entered at this stage
BlackRock- LMLaurion Capital Management
- CECelgene
- NSNovo Seeds
- BSBristol-Myers Squibb
Mubadala Capital
Casdin Capital
SoftBank- NHNovo Holdings
- FGFrontier IP Group
- UDUniversity of Dundee
SoftBank Vision Fund- MWMarshall Wace
- FMFarallon Capital Management
- PSPivotal Life Sciences
- GTGT Technologies
- GHGT Healthcare
Source: Dealroom Talent Intelligence.
Alumni founders
Former Exscientia employees who went on to found companies, sorted by Dealroom signal score.
MBMyricx BioEst. 2019
Andrew BellUnited Kingdom
Gregory VladimerAustria
CTCHARM TherapeuticsEst. 2021
Laksh AithaniUnited Kingdom
ATAffinia TherapeuticsEst. 2019
Rob Johnson.United StatesPatents
16 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Exscientia on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Dundee's PhaSER wins $2.7M Gates Foundation grant renewal for neglected-disease drugs
UK's Big Picture Bio raises $2M pre-seed to design cancer drug combinations
